Sign in
CompletedPhase 1

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Key facts

Who runs it
ModernaTX, Inc.
Where
Anderson, Atlanta, Columbus, Decatur, DeLand, Hollywood, Houston, Morehead City, Myrtle Beach, Peoria, Southfield, St. Petersburg, Sugar Land, and Wilmington, United StatesSee the 14 sitesAlso in 2 other countries, 16 sites
Status
Completed
Phase
Phase 1
People taking part
392 people enrolled
Started
14 Oct 2022
Ended
28 Feb 2024
Type of study
Interventional, 9 groups
Treatments tested
  • mRNA-1010
  • mRNA-1345
  • mRNA-1273.214
  • mRNA-1045
  • mRNA-1230
Record updated
8 March 2024

Who can take part

Age
50 years to 75 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Investigator assessment that participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures
  • Body mass index of 18 to 35 kilograms/square meter (kg/m\^2) (inclusive) at the Screening Visit(s)
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception or abstinence through 3 months following the vaccination, and not currently breastfeeding
  • Fully vaccinated for COVID-19 with an approved primary series according to the locally authorized or approved regimen. The most recent COVID-19 vaccine (primary series or booster) must be ≥120 days before (or less per local guidance) Day 1

Who cannot take part

  • Has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months before screening (for corticosteroids ≥10 milligrams (mg)/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study
  • Received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days before study injections (Day 1) or within 28 days after the study injection
  • Received a licensed seasonal influenza vaccine or any other investigational influenza or RSV vaccine within ≤180 days before Day 1
  • Tested positive for influenza or RSV by local health authority-approved testing methods within ≤180 days before Day 1
  • Significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 14 days, as defined by the United States Center for Disease Control (CDC) or the European Centre for Disease Prevention and Control as a high risk (close contact) of a COVID-19 case or known history of SARS-CoV-2 infection within the past 90 days before Day 1
  • Donated ≥450 mL of blood products within 28 days before the Screening Visit or plans to donate blood products during the study; Note: Other inclusion and exclusion criteria may apply
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results
  • Acutely ill or febrile (temperature ≥38.0°Celsius/[100.4°Fahrenheit]) 72 hours before or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window for re-evaluation and will retain their initially assigned participant number

Where in United States

Also in 2 other countries, 16 sites

  • Velocity Clinical ResearchAnderson, United States
  • Atlanta Center for Medical Research - Family MedicineAtlanta, United States
  • Centricity ResearchColumbus, United States
  • Cenexel IRA (iResearch Atlanta)Decatur, United States
  • DeLand, FloridaHospital not named in the registry
  • Research Centers of America (cenexel)Hollywood, United States
  • DM Clinical ResearchHouston, United States
  • Lucas Research, Inc. (Diabetes & Endocrinology Consultants PC)Morehead City, United States
  • Trial Management AssociatesMyrtle Beach, United States
  • Optimal ResearchPeoria, United States
  • DM Clinical ResearchSouthfield, United States
  • St. Petersburg, FloridaHospital not named in the registry
  • DM Clinical ResearchSugar Land, United States
  • Trial Management AssociatesWilmington, United States

About the trial

What the trial wants to find out

The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.

The 9 groups in the trial

  • mRNA-1010Treatment being tested

    Participants will receive a dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

  • mRNA-1345Treatment being tested

    Participants will receive a dose of mRNA-1345 by IM injection on Day 1.

  • mRNA-1273.214Treatment being tested

    Participants will receive a dose of mRNA-1273.214 by IM injection on Day 1.

  • mRNA-1045 Dose Level ATreatment being tested

    Participants will receive mRNA-1045 at Dose Level A by IM injection on Day 1.

    Treatment: mRNA-1045

  • mRNA-1045 Dose Level BTreatment being tested

    Participants will receive mRNA-1045 at Dose Level B by IM injection on Day 1.

    Treatment: mRNA-1045

  • mRNA-1045 Dose Level CTreatment being tested

    Participants will receive mRNA-1045 at Dose Level C by IM injection on Day 1.

    Treatment: mRNA-1045

  • mRNA-1230 Dose Level ATreatment being tested

    Participants will receive mRNA-1230 at Dose Level A by IM injection on Day 1.

    Treatment: mRNA-1230

  • mRNA-1230 Dose Level BTreatment being tested

    Participants will receive mRNA-1230 at Dose Level B by IM injection on Day 1.

    Treatment: mRNA-1230

  • mRNA-1230 Dose Level CTreatment being tested

    Participants will receive mRNA-1230 at Dose Level C by IM injection on Day 1.

    Treatment: mRNA-1230

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age
Record updated
8 March 2024